CASE STUDY PRA Revs Up Multiple Myeloma Study How We Exceeded Timelines for Site Activation & First Patient InPRA Revs Up Multiple Myeloma Study How We Exceeded Timelines for Site Activation & First Patient In Primary Endpoint Safety and efficacy PRA Services Full service Indication Multiple Myeloma Drug Class Thalidomide Analogues Study Phase III Business Segment Product Registration Regions North America Western Europe Central Europe Eastern Europe Asia Pacific STUDY DESCRIPTION Study 1: A Phase III, multi-center, randomized, open-label study to compare the efficacy and safety of Study Drug A in combination with low-dose Study Drug B versus high-dose Study Drug B in patients with refractory or relapsed and refractory multiple myeloma. Study 2: Open-label, single-arm stu

Join for free to read